Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
In development [GID-TA10159] Expected publication date: TBC
Search results
594 results
-
-
Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]
In development [GID-TA10110] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
In development [GID-TA10295] Expected publication date: TBC
-
Pembrolizumab for previously treated multiple myeloma (ID1139)
In development [GID-TA10193] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
In development [GID-TA10254] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC
-
Prostate cancer (hormone refractory) - atrasentan [ID390]
In development [GID-TAG379] Expected publication date: TBC
-
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
In development [GID-TA10221] Expected publication date: TBC
-
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
In development [GID-TA10404] Expected publication date: TBC
-
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)
In development [GID-TA10233] Expected publication date: TBC
-
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467
In development [GID-TA10353] Expected publication date: TBC
-
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
In development [GID-TAG320] Expected publication date: TBC
-
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
In development [GID-TA10177] Expected publication date: TBC
-
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
In development [GID-TAG435] Expected publication date: TBC
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]
In development [GID-TA10846] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC
-
Voclosporin with immunosuppressives for treating lupus nephritis [ID3962]
In development [GID-TA10878] Expected publication date: 25 January 2023
-
Autologous auto-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults ID1494
In development [GID-TA10424] Expected publication date: 14 December 2022
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 23 February 2023
-
Memokath-051 stent for ureteric obstruction
In development [GID-MT569] Expected publication date: 07 December 2022
-
Lower urinary tract symptoms in men: management
In development [GID-NG10300] Expected publication date: TBC
-
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
In development [GID-TA10539] Expected publication date: TBC
-
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development [GID-TA10822] Expected publication date: TBC
-
Focal resurfacing implants to treat articular cartilage damage in the knee
In development [GID-IPG10202] Expected publication date: 17 August 2022
-
Superficial venous arterialisation and selective venous occlusion for chronic limb threatening ischaemia in people with no other option for revascularisation
In development [GID-IPG10192] Expected publication date: 17 August 2022
-
Transcutaneous electrical stimulation of the trigeminal nerve for ADHD
In development [GID-IPG10210] Expected publication date: TBC
-
Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain
In development [GID-IPG10208] Expected publication date: TBC
-
Olaparib for adjuvant treatment of high-risk HER2-negative, BRCA-positive early breast cancer after chemotherapy [ID3893]
In development [GID-TA10903] Expected publication date: 03 January 2023
-
Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection
In development [GID-IPG10197] Expected publication date: 27 July 2022
-
Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation
In development [GID-IPG10198] Expected publication date: 27 July 2022
-
Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation
In development [GID-IPG10229] Expected publication date: 03 August 2022
-
Pegunigalsidase alfa for treating Fabry disease [ID3904]
In development [GID-TA10790] Expected publication date: TBC
-
Maternal and child nutrition
In development [GID-NG10191] Expected publication date: 22 November 2023
-
Removal, preservation and subsequent re-implantation of ovarian tissue to prevent symptoms from the menopause
In development [GID-IPG10170] Expected publication date: 21 September 2022
-
Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea
In development [GID-IPG10223] Expected publication date: 21 April 2023
-
Endoluminal gastroplication for gastro-oesophageal reflux disease
In development [GID-IPG10225] Expected publication date: 01 March 2023
-
Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia
In development [GID-IPG10214] Expected publication date: 21 September 2022
-
Nivolumab with radiation therapy for untreated glioblastoma ID1562
In development [GID-TA10443] Expected publication date: TBC
-
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
In development [GID-TA10452] Expected publication date: TBC
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Rehabilitation for chronic neurological disorders including acquired brain injury
In development [GID-NG10181] Expected publication date: 13 December 2023
-
Risankizumab for previously treated moderately to severely active Crohn's disease [ID3986]
In development [GID-TA10884] Expected publication date: 08 March 2023
-
Subarachnoid haemorrhage due to ruptured aneurysms
In development [GID-NG10097] Expected publication date: TBC
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer [ID3839]
In development [GID-TA10725] Expected publication date: TBC
-
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
In development [GID-TAG507] Expected publication date: TBC